Alfonso T. Perez

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

William B. White, Christopher P. Cannon, Simon Heller et al. · New England Journal of Medicine · 2013 · 2.5K citations · Full text

Medicine, Cardiology, Internal Medicine +14

A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

Ronald Goldberg, David M. Kendall, Mark A. Deeg et al. · Diabetes Care · 2005 · 795 citations · Full text

Medicine, Endocrinology, Pharmacology +14

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

Faı̈ez Zannad, Christopher P. Cannon, William C. Cushman et al. · The Lancet · 2015 · 754 citations · Full text

Medicine, Cardiology, Internal Medicine +17

Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy

Paulos Berhanu, Mark Kipnes, Mehmood Khan et al. · Diabetes and Vascular Disease Research · 2006 · 59 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

Ronald Goldberg, David M. Kendall, Mark A. Deeg et al. · Diabetes Care · 2005 · 49 citations · Full text

Medicine, Endocrinology, Pharmacology +14